HF
LGND icon

HRT Financial’s Ligand Pharmaceuticals LGND Stock Holding History

HRT Financial’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-31,266
Closed -$2.29M – 2697
2024
Q1 		$2.29M Buy
+31,266
New +$2.31M 0.01% 519
2023
Q2 		– Sell
-8,872
Closed -$652K – 2897
2023
Q1 		$652K Sell
8,872
-22,548
-72% -$1.6M 0.01% 1193
2022
Q4 		$2.1M Buy
31,420
+10,092
+47% +$656K 0.03% 571
2022
Q3 		$1.15M Buy
+21,328
New +$1.25M 0.01% 838
2022
Q1 		– Sell
-16,171
Closed -$1.56M – 3502
2021
Q4 		$1.56M Buy
+16,171
New +$1.49M 0.01% 804
2021
Q2 		– Sell
-15,184
Closed -$1.44M – 3215
2021
Q1 		$1.44M Buy
+15,184
New +$1.44M 0.01% 812
2020
Q3 		– Sell
-3,616
Closed -$252K – 2156
2020
Q2 		$252K Buy
+3,616
New +$229K 0.01% 1058
2019
Q4 		– Sell
-3,358
Closed -$208K – 1422
2019
Q3 		$208K Sell
3,358
-7,736
-70% -$486K 0.01% 1129
2019
Q2 		$790K Buy
+11,094
New +$817K 0.05% 311

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

HRT Financial's LGND Position: Q2 2024 in Review

HRT Financial sold out of Ligand Pharmaceuticals (LGND) in Q2 2024, closing a stake of 31,266 shares — an estimated $2.29M sold.

HRT Financial first reported a position in LGND in Q2 2019 and held it in 9 quarters. The position peaked at $2.29M in Q1 2024. 234 funds tracked by Wall St. Rank hold LGND as of Q2 2024.

  • HRT Financial reported no remaining Ligand Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • HRT Financial sold 31,266 Ligand Pharmaceuticals shares in Q2 2024, an estimated $2.29M.
  • HRT Financial first reported a position in Ligand Pharmaceuticals in Q2 2019 and held it in 9 quarters.
  • HRT Financial's Ligand Pharmaceuticals position peaked at $2.29M in Q1 2024.
  • 234 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2024.

Based on HRT Financial's 13F filing for Q2 2024, filed 12 Aug 2024.